Researchers from Centre National de la Recherche Scientifique and affiliated organizations presented the discovery and preclinical identification of novel inhibitors of metallo-beta-lactamases (MBLs). Synthesis and optimization of novel broad-spectrum inhibitors against most relevant MBLs, such as VIM-type enzymes and NDM-1, led to the identification of JMV-7061 as the lead from the series.
Tetra Bio-Pharma Inc. has signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 (onternabez) as a combination product with Qifenda (favipiravir) 400 mg, a commercial-stage broad-spectrum antiviral drug.
Researchers from Arbutus Biopharma Corp. presented preclinical data for the novel hepatitis B virus (HBV) capsid assembly inhibitor, AB-836, being developed for the treatment of chronic HBV infection.
Working from a lead tetrahydro-beta-carboline acid product which had been found to have antimalarial properties and to act as an inhibitor of MEP, Virginia Tech and University of Georgia scientists and their collaborators synthesized related compounds.
Arcturus Therapeutics Inc. has obtained an award for up to US$63.2 million from the Biomedical Advanced Research and Development Authority (BARDA) to expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform.
Immunoprecise Antibodies Ltd.'s Polytope TATX-03 antibody combination therapy has been shown to neutralize SARS-CoV-2 variants of concern, including the omicron BA.5 subvariant, in an authentic virus assay.
Academy of Military Medical Sciences (AMMS) has divulged 3C-like proteinase (viral) and 3C protease (viral) inhibitors reported to be useful for the treatment of viral infections.
Scientists have discovered a new antibiotic called evybactin that is able to selectively target Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB) lung infections. As described in NatureChemicalBiology on Aug. 22, 2022. the work is still at an early stage and requires further validation. But, if successful in clinical trials, evybactin could form part of a new group of specific antibiotics designed to target TB.
RSS
